FDA Inspection 1317706 — Adimmune Corporation
The FDA completed an inspection of Adimmune Corporation on Apr 2, 2026 in Taichung City. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Biologics.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Apr 2, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Taichung City (Taiwan)